Gilead Sciences joins GVN's pharma coalition

By The Science Advisory Board staff writers

June 30, 2021 -- The Global Virus Network (GVN), a coalition of virologists, announced that Gilead Sciences has joined its Healthcare and Pharma Center of Excellence Coalition.

The excellence coalition aims to use the expertise and resources of pharmaceutical companies to lead the charge against viruses threatening public health.

Gilead joins Abbott and Sanofi Pasteur in developing therapies and treatments for viral threats and diseases, including Zika, Ebola, and dengue.

Celdara joins global coalition to advance research
Celdara Medical announced a collaboration with the Global Virus Network, a coalition of human and animal virologists from 63 centers and 11 affiliates...
GVN adds Sanofi Pasteur as partner against viral threats
The Global Virus Network (GVN) has added Sanofi Pasteur, the vaccines business unit of Sanofi, as a member of the GVN Healthcare & Pharma Centers of Excellence...
Gilead partners with Gritstone for HIV vaccine, increases investment in Arcus
Gilead Sciences said it's collaborating with Gritstone Oncology to develop a vaccine-based immunotherapy aimed at providing a curative treatment for HIV....
Gilead Sciences to acquire Immunomedics for $21B
Gilead Sciences will acquire Immunomedics for $88 per share in cash, a transaction that values Immunomedics at approximately $21 billion. The deal...
Gilead licenses immunotherapy from Jounce
Gilead Sciences has exclusively licensed the JTX-1811 novel cancer immunotherapy program from Jounce Therapeutics.

Copyright © 2021

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter